microRNA 650 (miR-650)

microRNA 650 (miR-650) is a small, non-coding RNA molecule that functions in the post-transcriptional regulation of gene expression by binding to complementary sequences in target messenger RNAs (mRNAs), promoting their degradation or inhibiting their translation[1][4]. miR-650 is involved in a range of biological processes including cell proliferation, apoptosis, cell cycle regulation, epithelial-to-mesenchymal transition, and immune modulation[1][2][3]. It plays complex and sometimes dual roles in human disease, acting as either a tumor suppressor or oncogene depending on the cancer type, and has been studied in hepatocellular carcinoma, lung, gastric, breast, endometrial, thyroid, ovarian, prostate cancers, glioma, leukemia, and melanoma[1][3]. miR-650 regulates pathways such as the LATS2/YAP, Wnt/β-catenin, AKT/ERK, and NF-κB signaling axes, and targets multiple proteins including ING4, CDK1, LATS2, and CDK5[1][2][3]. Altered expression of miR-650 has also been linked to the pathogenesis of Alzheimer's disease by targeting genes such as APOE, PSEN1, and CDK5[2]. Its clinical utility is being explored both as a diagnostic biomarker and a potential therapeutic target, although context-dependent effects and delivery challenges remain significant hurdles[1][2][3].

Other names

MIR650hsa-mir-650MIRN650

Antisense inhibition (anti-miR), miRNA mimic therapy, Modulation of downstream protein-coding genes via direct sequence complementarity